This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) continued growth across the insured and self-insured medical, pharmacy, dental and behavioral health products and services.
Thermo Fisher (TMO) Completes the CorEvitas Acquisition
by Zacks Equity Research
Thermo Fisher's (TMO) latest buyout is likely to deliver $0.03 in adjusted earnings per share in 2024 and be marginally accretive in 2023.
Here's Why You Should Invest in Edward Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of a solid foundation for innovative therapies.
Time to Buy These Medical Stocks as Earnings Approach
by Shaun Pruitt
Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.
HCA Healthcare (HCA) Rises 24% in a Year: More Room to Run?
by Zacks Equity Research
HCA Healthcare (HCA) is well-poised for growth on the back of improved patient occupancy levels, effective telehealth services suite and solid cash-generating abilities.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on its strategic expansion in the global market and recovery within the Nutrition segment.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and acquisitions.
Myriad Genetics (MYGN) Unveils GeneSight Test Enhancement
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight report will contain details on how a patient's smoking history may affect their metabolism of certain medications.
Here's Why You Should Invest in Alcon (ALC) Stock Now
by Zacks Equity Research
Investors are optimistic about Alcon (ALC) owing to its strength in Surgical and Vision Care franchises and upbeat 2023 guidance.
Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Illumina (ILMN) shipped 109 NovaSeq X instruments in the second quarter, boosting its supply capacity to more than 390 instruments for fiscal 2023.
Haemonetics (HAE) Q1 Earnings Top Estimates, 2024 View Up
by Zacks Equity Research
The robust volume growth and price benefits in the Plasma business drive Haemonetics' (HAE) fiscal first-quarter performance.
QIAGEN (QGEN) Receives FDA Approval for AYVAKIT CDX Test
by Zacks Equity Research
QIAGEN's (QGEN) latest approval adds to its leading portfolio in precision medicine, including 12 FDA-approved companion diagnostics.
Here's Why You Should Invest in Medtronic (MDT) Stock Now
by Zacks Equity Research
Investors are optimistic about Medtronic (MDT) on strong growth prospects within the Neurosurgery portfolio and upbeat 2024 guidance.
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss
by Zacks Equity Research
Strong testing volume improvement across all businesses drives Myriad Genetics' (MYGN) Q2 performance.
National Vision (EYE) Gains From Store Openings Amid Cost Woes
by Zacks Equity Research
National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.
Bio-Rad (BIO) Beats on Q2 Earnings Estimates, Cuts 2023 View
by Zacks Equity Research
Growth across the Life Science portfolio and strong double-digit growth for ddPCR drive Bio-Rad (BIO) Q2 performance.
Select Medical (SEM) Q2 Earnings Meet, Revenues Rise Y/Y
by Zacks Equity Research
Select Medical's (SEM) Q2 results reflect solid segmental revenues, attributable to higher patient days and outpatient visits. Management projects adjusted EPS of $1.86-$2.03 for 2023.
Teleflex (TFX) Q2 Earnings Top Estimates, 2023 Sales View Up
by Zacks Equity Research
Strong performances in its Vascular, Interventional and Surgical businesses drives Teleflex (TFX) Q2 revenues.
Here's Why You Should Buy SmileDirectClub (SDC) Stock Now
by Zacks Equity Research
Investors are likely to benefit from the SmileDirectClub (SDC) stock, backed by strategic alliances and targeted long-term growth.
Penumbra (PEN) Q2 Earnings Top Estimates, Sales View Raised
by Zacks Equity Research
Penumbra's (PEN) U.S. thrombectomy records 50% year-over-year growth, while the international Vascular business sees relatively flat sales in the second quarter.
Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 53.57% and 3.28%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Alcon, Hologic and Penumbra
by Zacks Equity Research
Alcon, Hologic and Penumbra have been highlighted in this Industry Outlook article.
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on rising demand for digital health. ALC, HOLX and PEN are set to gain the most. Yet, ongoing inflation, in the form of rising freight and raw material costs, is disrupting the trend.
Abbott (ABT) Q2 Earnings & Revenues Beat Estimates, Down Y/Y
by Zacks Equity Research
Abbott (ABT) delivers better-than-expected earnings and revenues in the second quarter of 2023
Should iShares Morningstar Small-Cap Growth ETF (ISCG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCG